2876-22-4

Usage

Safety Profile

Mutation data reported. When heated to decomposition it emits toxic vapors of NOx.

InChI:InChI=1/C12H9N3/c13-8-4-3-7-11-12(8)15-10-6-2-1-5-9(10)14-11/h1-7H,13H2

Upstream product

• 550-89-0 phenazine-1-carboxamide 
• 2876-34-8 1-nitro-phenazine 5-oxide 
• 38919-26-5 bis(2-aminophenyl)amine 
• 64-17-5 ethanol 
• 119-70-0 4,4'-diaminodiphenylamine-2'-sulfonic acid 
• 129-93-1 6,8-dianilino-naphthalene-1-sulfonic acid 
• 62-53-3 aniline 
• 2538-68-3 tubermycin B 
• 54420-95-0 6-nitrodiphenylamine-2-carboxylic acid 
• 573-54-6 2-bromo-3-nitro-benzoic acid 
• 118-97-8 4-chloro-3,5-dinitrobenzoic acid 
• 95-54-5 1,2-diamino-benzene 
• 606-22-4 2,6-dinitroaniline 
• 609-73-4 o-nitroiodobenzene 

Downstream Products

• 528-71-2 phenazin-1-ol 

Relevant academic research and scientific papers

Formation of 1-aminophenazine from 3,4-dihydrophenazin-1(2H)-one oxime in the system acetylene–KOH–DMSO

The reaction of 3,4-dihydrophenazin-1(2H)-one oxime with acetylene in the superbasic system KOH–DMSO afforded 1-aminophenazine in 32% yield instead of the expected pyrrolophenazine. The same product was also obtained under analogous conditions in the abse

Design, synthesis and biological evaluations of diverse Michael acceptor-based phenazine hybrid molecules as TrxR1 inhibitors

A series of novel phenazine derivatives (1~27) containing the Michael acceptor scaffolds were designed and synthesized in this study. Some compounds exhibited selective cytotoxicity against Bel-7402 cancer cell line in vitro, in which compound 26 were found to have the best antiproliferative activity. Meanwhile, compound 26 showed no obvious cell toxicity against human normal liver epithelial L02 cells, which means this compound possessed a better safety potential. In the following research, compound 26 was verified to inhibit TrxR1 enzyme activity, ultimately resulting in cellular molecular mechanism events of apoptosis including growth of intracellular ROS level, depletion of reduced Trx1, liberation of ASK1 and up-regulation of p38, respectively. Together, all these evidences implicated that compound 26 acted as the TrxR1 inhibitor against Bel-7402 cells, and could activate apoptosis through the ROS-Trx-ASK1-p38 pathway.

Phenazine derivative serving as TrxR1 inhibitor, intermediate product, preparation methods of phenazine derivative and intermediate product and application of phenazine derivative

The invention discloses a phenazine derivative which has a structure shown in a general formula I and serves as a TrxR1 inhibitor, an intermediate product, and a preparation method and application ofthe phenazine derivative. In the formula I, R is H or CH3; R is selected from H, CH2N(CH3)2, phenyl, (4-fluoro)-phenyl, (3-trifluoromethyl)-phenyl, (4-chloro)-phenyl and (2,5-dichloro)-phenyl; and R is H. The phenazine derivative disclosed by the invention has significant inhibitory activity on TrxR1, especially has significant anti-proliferative activity on HepG2 cell strains, and can beused for preparing anti-tumor drugs.

PHENAZINIUM MEDIATORS

The present invention relates to a chemical compound or a salt or solvate thereof being an 1-amino-phenazine derivative and to uses thereof. The present invention further relates to a chemistry matrix and to a test element comprising the aforesaid chemical compound. Moreover, the present invention relates to a method for determining the amount of an analyte in a sample, comprising contacting said sample with a chemistry matrix according to the present invention, estimating the amount of electrons liberated or consumed by the chemistry matrix in the presence of said liquid sample, and thereby determining the amount of an analyte in a liquid sample.

PHENAZINE DERIVATIVES AS ANTIMICROBIAL AGENTS

The present invention provides novel phenazine derivatives, such as compounds of Formula (I) and (II), and pharmaceutically acceptable salts thereof. The compounds of the invention are expected to be anitmicrobial agents and may act by a microbial warfare strategy (e.g., a reactive oxygen species (ROS)-based competition strategy). The present invention also provides pharmaceutical compositions, kits, uses, and methods that involve the compounds of the invention and may be useful in preventing or treating a microbial infection (e.g., a bacterial infection) in a subject, inhibiting the growth and/or reproduction of a microorganism (e.g., a bacterium), killing a microorganism (e.g., a bacterium), inhibiting the formation and/or growth of a biofilm, or reducing or clearing a biofilm.

Phenazine antibiotic inspired discovery of potent bromophenazine antibacterial agents against Staphylococcus aureus and Staphylococcus epidermidis

Nearly all clinically used antibiotics have been (1) discovered from microorganisms (2) using phenotype screens to identify inhibitors of bacterial growth. The effectiveness of these antibiotics is attributed to their endogenous roles as bacterial warfare agents against competing microorganisms. Unfortunately, every class of clinically used antibiotic has been met with drug resistant bacteria. In fact, the emergence of resistant bacterial infections coupled to the dismal pipeline of new antibacterial agents has resulted in a global health care crisis. There is an urgent need for innovative antibacterial strategies and treatment options to effectively combat drug resistant bacterial pathogens. Here, we describe the implementation of a Pseudomonas competition strategy, using redox-active phenazines, to identify novel antibacterial leads against Staphylococcus aureus and Staphylococcus epidermidis. In this report, we describe the chemical synthesis and evaluation of a diverse 27-membered phenazine library. Using this microbial warfare inspired approach, we have identified several bromophenazines with potent antibacterial activities against S. aureus and S. epidermidis. The most potent bromophenazine analogue from this focused library demonstrated a minimum inhibitory concentration (MIC) of 0.78-1.56 μM, or 0.31-0.62 μg mL-1, against S. aureus and S. epidermidis and proved to be 32- to 64-fold more potent than the phenazine antibiotic pyocyanin in head-to-head MIC experiments. In addition to the discovery of potent antibacterial agents against S. aureus and S. epidermidis, we also report a detailed structure-activity relationship for this class of bromophenazine small molecules.

Triazine dyestuffs

Reactive azine dyestuffs of the formula: SPC1 Wherein Am is selected from a group consisting of anilino, di(lower alkyl)amino and N(lower alkyl)benzylamino radicals, one of Y1 and Y2 is H or SO3 H and the other is H or an alkyl or alkoxy group of 1-4 carbon atoms, One of X1 or X2 is H, SO3 H, --SO2 CH2 CH2 OSO3 H or --SO2 CH=CH2 and the other is H, an alkyl or alkoxy group of 1-4 carbon atoms, Cl or CO2 H, X3 is H, an alkyl group of 1-4 carbon atoms or SO3 H, when the dotted fused ring is present B is absent and when the dotted fused ring is absent B is H or an alkyl or alkoxy group of 1-4 carbon atoms, At least one of the pendant benzene nuclei contains a NHQ group where Q is a cellulose-reactive group except when X1 or X2 is --SO2 CH2 CH2 OSO3 H or --SO2 CH=CH2 and the dyestuff as a whole contains at least 2 sulphonic acid groups. The products are reactive dyes for cellulose which are colored in strong bright blue or reddish-blue shades of excellent fastness to washing and of a reasonable fastness to light, especially in respect of wet fading.